PDCD1 and head and neck squamous cell carcinoma: In 2021, a meta-analysis and systematic review was published that aimed to assess the efficacy of anti-PD-1 therapy vs. anti-PD-L1 therapy vs. standard chemotherapy in patients with relapsed or metastatic HNSCC.